Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review

Ruiz‐Negrón, Natalia; Menon, Jyothi U.; King, Jordan B.; José, Ma; Bellows, Brandon K.

doi:10.1007/s40273-018-00761-6

Cited by 18 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most commonly adopted instruments for quality assessment include CHEERS checklist, Quality of Health Economics Studies (QHES) instrument, the Philips and the Drummond checklists, et al CHEERS checklist was developed by international experts, and jointly endorsed by many journals [ 19 , 45 , 46 ]. A plenty of previous studies have adopted the CHEERS checklist for assessing the quality of published economic studies [ 47 , 48 ]. Therefore, the quality assessment was conducted using the CHEERS checklists in the present systematic review.…”

Section: Discussionmentioning

confidence: 99%

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

et al. 2020

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs. Objectives The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC). Methods We searched the PubMed, Web of Science, and Cochrane Library for studies comparing the cost effectiveness of ICIs for NSCLC. Potential studies identified were independently checked for eligibility by two authors, with disagreement resolved by a third reviewer. Quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards checklists. Results A total of 22 economic studies were included. Overall reporting of the identified studies largely met CHEERS recommendations. In the first-line setting, for advanced or metastatic NSCLC patients with PD-L1 � 50%, pembrolizumab appeared cost-effective compared with platinum-based chemotherapy in the US and Hong Kong (China), but not in the UK and China. The cost-effectiveness of pembrolizumab versus chemotherapy for first-line treatment of NSCLC in PD-L1 � 1% patients remained obscure. Regardless of PD-L1 expression status, pembrolizumab in combination with chemotherapy could be a cost-effective first-line therapy in the US. On the contrary, addition of atezolizumab to the combination of

show abstract

Section: Discussionmentioning

confidence: 99%

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although many studies have evaluated individual aspects, such as the profitability of the treatments, the significant heterogeneity among them prevents reaching a homoge-Occupational Diseases and Environmental Medicine neous synthesis of the results. The standardized methodology and the improved reports would allow more reliable comparisons between the studies [27]. Strategies are proposed to maximize the results, employing, when possible, agents that address both pain and comorbidities in order to restore function and improve function, quality of life of the patient [28].…”

Section: Discussionmentioning

confidence: 99%

Proposed Protocol for Neuropathic Pain Assessment

Herrero¹,

Torre²,

Barbero³

2020

ODEM

View full text Add to dashboard Cite

Introduction: Pain with neuropathic characteristics is one of the most limiting as a consequence of injury or disease that affects the somatosensory system. Objective: An assessment protocol is proposed to quantify the impact of neuropathic pain integrating personal, clinical, work and social aspects and to establish guidelines in its management and evolutionary control. Method: The medical literature on neuropathic pain and its impact is reviewed as a basis for including the variables that must be part of the protocol. Results: The variables are quantified individually and by groups of factors. The final result is stratified into four grades (mild, moderate, severe, extreme), which will serve for the subsequent control, monitoring and prevention of risks. Conclusion: The proposed protocol evaluates the impact of neuropathic pain in all aspects of the person who suffers it and quantifies the results establishing degrees for its control, follow-up and clinical, social and occupational intervention.

show abstract

“…In addition, incorporating the results of sensitivity analyses should be considered. 56,57 When synthesizing numeric values, articles will likely be excluded based on missing information necessary for judging eligibility, applicability, homogeneity, etc. For example, missing demographic characteristics of the population analyzed may make it impossible to determine if the study applies to an age group that the SR-CCEO focuses on.…”

Section: Performing Data Synthesismentioning

confidence: 99%

Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report

et al. 2021

View full text Add to dashboard Cite

Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review

Cited by 18 publications

References 51 publications

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

Proposed Protocol for Neuropathic Pain Assessment

Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report

Contact Info

Product

Resources

About